Research Progress of Adoptive Cell Immunotherapy in Cervical Cancer

doi:10.12280/gjfckx.20240124

Abstract

Abstract:

Cervical cancer is one of the most common malignant tumors among women. The 5-year survival rate of recurrent or metastatic cervical cancer is only 17% and the clinical treatment is very tricky. Programmed death-1(PD-1) monoclonal antibody has been used as a first-line treatment for recurrent or metastatic cervical cancer. However, the bottlenecks for PD-1 monoclonal antibody monotherapy are relatively lower objective response rate and higher drug resistance rate, which limits its clinical application. Recently, adoptive cell immunotherapy altered the landscape of cancer immunotherapy, which achieved antitumor effects by infusing antitumor cells back to the body. Currently, there are mainly three types of adoptive cell immunotherapy including tumor-infiltrating lymphocyte, T-cell receptor-engineered T cells and chimeric antigen receptor T-cell. Relative studies have demonstrated the significant value of adoptive cell immunotherapy on improvement of survival and prognosis for patients with advanced cervical cancer. The principles, biological characteristics, applications and limitations for adoptive cell immunotherapy are summarized in the review. Optimizing the productive technology and being combined with other oncological treatment may supply new ideas for cervical cancer immunotherapy.

Key words: Uterine cervical neoplasms, Immunotherapy, Adoptive cell immunotherapy, Tumor-infiltrating lymphocyte, T-cell receptor-engineered T cell, Chimeric antigen receptor T-cell

ZHANG Lan-yue, SHEN Fu-jin. Research Progress of Adoptive Cell Immunotherapy in Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2024, 51(3): 253-257.

References 29

[1]	Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials[J]. Cancer Treat Rev, 2022,106:102385. doi: 10.1016/j.ctrv.2022.102385.
[2]	Global cancer burden growing, amidst mounting need for services[J]. Saudi Med J, 2024, 45(3):326-327.
[3]	Mauricio D, Zeybek B, Tymon-Rosario J, et al. Immunotherapy in Cervical Cancer[J]. Curr Oncol Rep, 2021, 23(6):61. doi: 10.1007/s11912-021-01052-8. pmid: 33852056
[4]	Zhang Z, Pan Z, Li Q, et al. Rational design of ICD-inducing nanoparticles for cancer immunotherapy[J]. Sci Adv, 2024, 10(6):eadk0716. doi: 10.1126/sciadv.adk0716.
[5]	Awadasseid A, Zhou Y, Zhang K, et al. Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy[J]. Biomed Pharmacother, 2023,157:114057. doi: 10.1016/j.biopha.2022.114057.
[6]	Ferrall L, Lin KY, Roden R, et al. Cervical Cancer Immunotherapy: Facts and Hopes[J]. Clin Cancer Res, 2021, 27(18):4953-4973. doi: 10.1158/1078-0432.CCR-20-2833. pmid: 33888488
[7]	Wang S, Sun J, Chen K, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors[J]. BMC Med, 2021, 19(1):140. doi: 10.1186/s12916-021-02006-4. pmid: 34112147
[8]	Meaningful Response to TILs in NSCLC[J]. Cancer Discov, 2021, 11(9):2117-2118. doi: 10.1158/2159-8290.CD-NB2021-0370. pmid: 34353853
[9]	Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells[J]. J Clin Oncol, 2015, 33(14):1543-1550. doi: 10.1200/JCO.2014.58.9093. pmid: 25823737
[10]	Stevanović S, Helman SR, Wunderlich JR, et al. A Phase Ⅱ Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers[J]. Clin Cancer Res, 2019, 25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722. pmid: 30518633
[11]	Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.[J]. J Clin Oncol, 2019, 37(Suppl 15):2538. doi: 10.1200/JCO.2019.37.15_suppl.2538.
[12]	Huang H, Nie CP, Liu XF, et al. PhaseⅠstudy of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer[J]. J Clin Invest, 2022, 132(15):e157726. doi: 10.1172/JCI157726.
[13]	Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. pmid: 34385708
[14]	Zhu Y, Zhou J, Zhu L, et al. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer[J]. Hum Vaccin Immunother, 2022, 18(5):2060019. doi: 10.1080/21645515.2022.2060019.
[15]	Tang Y, Zhang A, Chen G, et al. Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives[J]. Mol Ther Oncolytics, 2021, 22:410-430. doi: 10.1016/j.omto.2021.07.006.
[16]	Yuan Y, Cai X, Shen F, et al. HPV post-infection microenvironment and cervical cancer[J]. Cancer Lett, 2021, 497:243-254. doi: 10.1016/j.canlet.2020.10.034. pmid: 33122098
[17]	Scholten KB, Turksma AW, Ruizendaal JJ, et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer[J]. J Transl Med, 2011,9:147. doi: 10.1186/1479-5876-9-147.
[18]	Draper LM, Kwong ML, Gros A, et al. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6[J]. Clin Cancer Res, 2015, 21(19):4431-4439. doi: 10.1158/1078-0432.CCR-14-3341. pmid: 26429982
[19]	Doran SL, Stevanović S, Adhikary S, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, PhaseⅠ/ⅡStudy[J]. J Clin Oncol, 2019, 37(30):2759-2768. doi: 10.1200/JCO.18.02424.
[20]	Nagarsheth NB, Norberg SM, Sinkoe AL, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers[J]. Nat Med, 2021, 27(3):419-425. doi: 10.1038/s41591-020-01225-1. pmid: 33558725
[21]	冯娟, 李佳涛, 庄娜. CRISPR/Cas9敲除内源TCR增强TCR-T细胞对HPV16阳性宫颈癌SiHa细胞的杀伤[J]. 中国肿瘤生物治疗杂志, 2023, 30(5):373-379. doi: 10.3872/j.issn.1007-385x.2023.05.002.
[22]	Norberg SM, Hinrichs CS. Engineered T cell therapy for viral and non-viral epithelial cancers[J]. Cancer Cell, 2023, 41(1):58-69. doi: 10.1016/j.ccell.2022.10.016.
[23]	Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021, 11(4):69. doi: 10.1038/s41408-021-00459-7. pmid: 33824268
[24]	Jogalekar MP, Rajendran RL, Khan F, et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments[J]. Front Immunol, 2022,13:925985. doi: 10.3389/fimmu.2022.925985.
[25]	Zhang X, Zhu L, Zhang H, et al. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges[J]. Front Immunol, 2022,13:927153. doi: 10.3389/fimmu.2022.927153.
[26]	Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, et al. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma[J]. Front Immunol, 2022,13:991092. doi: 10.3389/fimmu.2022.991092.
[27]	Rosenberg S. CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer[EB/OL]. [2019-10-14]. https://www.clinicaltrials.gov/study/NCT01583686?term=NCT01583686&rank=1.
[28]	Hebei Senlang Biotechnology. Anti-PD-L1 armored anti-CD22 CAR-T/CAR-TILs targeting patients with solid tumors[EB/OL]. [2021-05-27]. https://www.clinicaltrials.gov/study/NCT04556669.
[29]	Chang LJ. Intervention of CAR-T against cervical cancer[EB/OL]. [2019-09-19]. https://www.clinicaltrials.gov/study/NCT03356795.